This week on the Readout LOUD
How likely is it for President Trump's new drug-pricing plan to be implemented? Why have investors seemed unbothered by the proposal? And will we see a return of Elizabeth Holmes' blood-testing ambitions? We discuss all that and more on this week's episode of "The Readout LOUD," STAT's biotech podcast. We chat about the mixed sentiment in biotech markets these days and a new blood-testing company formed by Holmes' husband. We also bring on STAT's D.C. correspondent Daniel Payne to talk about Trump's "most-favored nation" drug pricing policy and health secretary Robert F. Kennedy Jr.'s recent congressional hearing. Listen Now For more on Trump's drug-pricing policy, go here; to read more on the key questions surrounding the proposal, go here; for more on Kennedy's hearings, go here and here; and to learn more the new blood-testing company, go here and here. Subscribe to the podcast on Apple Podcasts or Spotify to never miss an episode Visit the archive to see past episodes |
|
| STAT, 1 Exchange Place, Boston, MA | ©2025, All Rights Reserved. | |
|
No comments